Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ENOV Enovis Corporation | ABBV AbbVie |
|---|---|---|
| Price | $18.04 +1.3% | $263.96 -0.0% |
| StockIQ Score | 37F Weak Risk: High | 59C Moderate Risk: High |
| Technical | 21F | 88A |
| Fundamental | 30F | 57C |
| Growth | 48D+ | 34F |
| Fair Value | 38F | 33F |
| News | 62C+ | 100A+ |
| Quality | 42D | 42D |
| Risk | 40D | 36F |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Enovis (ENOV) has a weaker overall rating ("WEAK" vs. "MODERATE") and significantly lower scores across most categories. Its technical score (6) is far below AbbVie’s (58), and its fundamental score (30) is also much weaker than AbbVie’s (56). AbbVie leads in stability and core strength, while Enovis shows higher growth potential (48 vs. 34) but weaker valuation (38 vs. 33). AbbVie is stronger in fundamentals and technicals.
